DrSanjeev (@drsanjeev1980) 's Twitter Profile
DrSanjeev

@drsanjeev1980

ID: 817856060

calendar_today11-09-2012 17:39:36

2,2K Tweet

1,1K Takipรงi

1,1K Takip Edilen

Haematologica (@haematologica) 's Twitter Profile Photo

Find here the new simplified index for stratifying older Hodgkin lymphoma patients as fit, unfit, or frail. haematologica.org/article/view/1โ€ฆ

Find here the new simplified index for stratifying older Hodgkin lymphoma patients as fit, unfit, or frail.
haematologica.org/article/view/1โ€ฆ
DrSanjeev (@drsanjeev1980) 's Twitter Profile Photo

Teclistamab based treatment in a post Transplant Relapse High risk MM, after Daratumumab failure, patient had multiple EMDs at relapse, excellent response For EMDs by Teclistamab.

Teclistamab based treatment in a post Transplant Relapse High risk MM, after Daratumumab failure, patient had multiple EMDs at relapse, excellent response For EMDs by Teclistamab.
Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

As one of the principal academic beneficiaries of Dr. Brian Durieโ€™s mentorship, guidance, and kindness I am heartbroken to hear of his passing. His contributions to myeloma and oncology are without parallel. Charismatic, brilliant, dedicated, Dr. Durie has had a huge impact on

As one of the principal academic beneficiaries of Dr. Brian Durieโ€™s mentorship, guidance, and kindness I am heartbroken to hear of his passing. 

His contributions to myeloma and oncology are without parallel. Charismatic, brilliant, dedicated, Dr. Durie has had a huge impact on
IACH (@theiach) 's Twitter Profile Photo

๐Ÿ“ข ๐˜‹๐˜ฐ๐˜ฏโ€™๐˜ต ๐˜ฎ๐˜ช๐˜ด๐˜ด ๐˜ฐ๐˜ถ๐˜ณ ๐˜ฏ๐˜ฆ๐˜น๐˜ต ๐˜๐˜ˆ๐˜Š๐˜ ๐˜ž๐˜ฆ๐˜ฃ๐˜ช๐˜ฏ๐˜ข๐˜ณ! ๐—›๐—ถ๐—ด๐—ต๐—น๐—ถ๐—ด๐—ต๐˜๐˜€ ๐—ณ๐—ฟ๐—ผ๐—บ ๐—œ๐— ๐—ฆ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฑ: ๐—” ๐—™๐—ผ๐—ฐ๐˜‚๐˜€ ๐—ผ๐—ป ๐—–๐—˜๐—Ÿ๐— ๐—ผ๐——๐˜€ ๐˜ฑ๐˜ณ๐˜ฆ๐˜ด๐˜ฆ๐˜ฏ๐˜ต๐˜ฆ๐˜ฅ ๐˜ฃ๐˜บ ๐˜‹๐˜ณ. ๐˜™๐˜ข๐˜ฉ๐˜ถ๐˜ญ ๐˜‰๐˜ข๐˜ฏ๐˜ฆ๐˜ณ๐˜ซ๐˜ฆ๐˜ฆ ๐Ÿ—“ ๐˜”๐˜ฐ๐˜ฏ๐˜ฅ๐˜ข๐˜บ, ๐˜–๐˜ค๐˜ต 20 | โฐ 6:30 ๐˜—๐˜” ๐˜Š๐˜Œ๐˜› ๐Ÿ”— ๐—™๐—ฟ๐—ฒ๐—ฒ

๐Ÿ“ข ๐˜‹๐˜ฐ๐˜ฏโ€™๐˜ต ๐˜ฎ๐˜ช๐˜ด๐˜ด ๐˜ฐ๐˜ถ๐˜ณ ๐˜ฏ๐˜ฆ๐˜น๐˜ต ๐˜๐˜ˆ๐˜Š๐˜ ๐˜ž๐˜ฆ๐˜ฃ๐˜ช๐˜ฏ๐˜ข๐˜ณ!

๐—›๐—ถ๐—ด๐—ต๐—น๐—ถ๐—ด๐—ต๐˜๐˜€ ๐—ณ๐—ฟ๐—ผ๐—บ ๐—œ๐— ๐—ฆ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฑ: ๐—” ๐—™๐—ผ๐—ฐ๐˜‚๐˜€ ๐—ผ๐—ป ๐—–๐—˜๐—Ÿ๐— ๐—ผ๐——๐˜€
๐˜ฑ๐˜ณ๐˜ฆ๐˜ด๐˜ฆ๐˜ฏ๐˜ต๐˜ฆ๐˜ฅ ๐˜ฃ๐˜บ ๐˜‹๐˜ณ. ๐˜™๐˜ข๐˜ฉ๐˜ถ๐˜ญ ๐˜‰๐˜ข๐˜ฏ๐˜ฆ๐˜ณ๐˜ซ๐˜ฆ๐˜ฆ

๐Ÿ—“ ๐˜”๐˜ฐ๐˜ฏ๐˜ฅ๐˜ข๐˜บ, ๐˜–๐˜ค๐˜ต 20 | โฐ 6:30 ๐˜—๐˜” ๐˜Š๐˜Œ๐˜›

๐Ÿ”— ๐—™๐—ฟ๐—ฒ๐—ฒ
IACH (@theiach) 's Twitter Profile Photo

๐ŸŽ“ ๐˜•๐˜ฆ๐˜ธ ๐˜๐˜ˆ๐˜Š๐˜ ๐˜ž๐˜ฆ๐˜ฃ๐˜ช๐˜ฏ๐˜ข๐˜ณ ๐˜ฐ๐˜ฏ ๐˜ด๐˜ช๐˜ต๐˜ฆ! ๐—›๐—ผ๐—ฑ๐—ด๐—ธ๐—ถ๐—ป ๐—น๐˜†๐—บ๐—ฝ๐—ต๐—ผ๐—บ๐—ฎ ๐—ณ๐—ฟ๐—ผ๐—ป๐˜๐—น๐—ถ๐—ป๐—ฒ ๐˜๐—ต๐—ฒ๐—ฟ๐—ฎ๐—ฝ๐˜†: ๐˜„๐—ต๐—ฎ๐˜'๐˜€ ๐—ป๐—ฒ๐˜„? ๐˜ธ๐˜ช๐˜ต๐˜ฉ ๐˜ˆ๐˜ญ๐˜ช ๐˜‰๐˜ข๐˜ป๐˜ข๐˜ณ๐˜ฃ๐˜ข๐˜ค๐˜ฉ๐˜ช ๐Ÿ“ฝ๏ธ๐˜•๐˜ฐ๐˜ธ ๐˜ข๐˜ท๐˜ข๐˜ช๐˜ญ๐˜ข๐˜ฃ๐˜ญ๐˜ฆ ๐˜ฐ๐˜ฏ ๐˜ฅ๐˜ฆ๐˜ฎ๐˜ข๐˜ฏ๐˜ฅ ๐Ÿ”—๐˜ž๐˜ข๐˜ต๐˜ค๐˜ฉ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ง๐˜ถ๐˜ญ๐˜ญ ๐˜ธ๐˜ฆ๐˜ฃ๐˜ช๐˜ฏ๐˜ข๐˜ณ ๐˜ง๐˜ฐ๐˜ณ

Ravi Kumar (@ravi00151) 's Twitter Profile Photo

๐Ÿ’‰ Rituximab: The B-Cell Assassinโš”๏ธ ๐Ÿงฌ A chimeric monoclonal antibody (IgG1ฮบ) targeting CD20 on pre-B and mature B cells ๐Ÿšซ Not expressed on stem cells or plasma cells โ†’ allows B-cell reconstitution later โš™๏ธ Mechanism of Action ๐ŸŽฏ Binds CD20 โ†’ induces B-cell depletion

๐Ÿ’‰ Rituximab: The B-Cell Assassinโš”๏ธ

๐Ÿงฌ A chimeric monoclonal antibody (IgG1ฮบ) targeting CD20 on pre-B and mature B cells
๐Ÿšซ Not expressed on stem cells or plasma cells โ†’ allows B-cell reconstitution later

โš™๏ธ Mechanism of Action

๐ŸŽฏ Binds CD20 โ†’ induces B-cell depletion
Rishabh Jain (@drrishabhonco) 's Twitter Profile Photo

๐Ÿšจ CINV control gets PERSONALIZED MyRisk Phase IV RCT in MEC, high-risk pts by risk-score ๐Ÿงช Arms: NEPA (Netupitant + Palonosetron) + DEX vs 5-HT3RA+DEX (SOC) ๐ŸŽฏ Primary: Complete response 0-120 h across 3 cycles ๐Ÿ“Š Results โ€ข CR per-cycle: 81.0% vs 71.8% โ†’ OR 1.67, p=0.012

๐Ÿšจ CINV control gets PERSONALIZED

MyRisk Phase IV RCT in MEC, high-risk pts by risk-score 
๐Ÿงช Arms: NEPA (Netupitant + Palonosetron) + DEX vs 5-HT3RA+DEX (SOC)
๐ŸŽฏ Primary: Complete response 0-120 h across 3 cycles

๐Ÿ“Š Results
โ€ข CR per-cycle: 81.0% vs 71.8% โ†’ OR 1.67, p=0.012
Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

Updated mSMART guidelines on treatment of newly diagnosed myeloma. Major change: For standard risk myeloma, doublet maintenance (lenalidomide plus anti CD38) recommended if MRD+ post transplant. msmart.org/mm-treatment-gโ€ฆ

Updated mSMART guidelines on treatment of newly diagnosed myeloma. 

Major change: For standard risk myeloma, doublet maintenance (lenalidomide plus anti CD38) recommended if MRD+ post transplant. 

msmart.org/mm-treatment-gโ€ฆ
Dr Rudra Narayan swain M.D (@rudra09s025) 's Twitter Profile Photo

๐Ÿงต IMiDs โ†’ CELMoDs: The Evolution of Cereblon Modulation in Myeloma ๐Ÿ’Š Immunomodulatory drugs (IMiDs) like lenalidomide/pomalidomide transformed MM therapy โ€” but refractoriness is common after prolonged use. ๐Ÿ“ˆ CELMoDs โ€” iberdomide & mezigdomide โ€” next-gen cereblon modulators

๐Ÿงต IMiDs โ†’ CELMoDs: The Evolution of Cereblon Modulation in Myeloma

๐Ÿ’Š Immunomodulatory drugs (IMiDs) like lenalidomide/pomalidomide transformed MM therapy โ€” but refractoriness is common after prolonged use.

๐Ÿ“ˆ CELMoDs โ€” iberdomide & mezigdomide โ€” next-gen cereblon modulators
Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

Breaking: And Iโ€™m glad. This is an important option we need for patients with myeloma. FDA has approved belantamab in combination with bortezomib and dex (BVd) for relapsed or refractory multiple myeloma in patients who have received at least two prior lines of therapy,

Rishabh Jain (@drrishabhonco) 's Twitter Profile Photo

๐Ÿงฌ Not all DLBCLs are created equal - POLA knows the difference. ๐Ÿ“Š Real-world (n = 740, 2015โ€“24) Polatuzumab used in ๐Ÿ”นFrontline (305) ๐Ÿ”นR/R (435) COO classified by Hans IHC algorithm ๐Ÿ”ฅ R/R LBCL: โ€ขORR 59.7% vs 36.3% โžœ OR 2.6 (p<0.0001) โ€ขCR 35.7% vs 17.7% โžœ OR 2.6

๐Ÿงฌ Not all DLBCLs are created equal - POLA knows the difference.

๐Ÿ“Š Real-world (n = 740, 2015โ€“24)
Polatuzumab used in 
๐Ÿ”นFrontline (305) 
๐Ÿ”นR/R (435)
COO classified by Hans IHC algorithm

๐Ÿ”ฅ R/R LBCL:
โ€ขORR 59.7% vs 36.3% โžœ OR 2.6 (p&lt;0.0001)
โ€ขCR 35.7% vs 17.7% โžœ OR 2.6